A Phase 3, Multicenter, Open-Label, Randomized Clinical Trial to evaluate Safety and Immunogenicity of ROTAVAC -20C and Rotavac 5CM administered at Birth (Neonatal Schedule) and Additional Dose versus Infant Schedule against Rotavirus Gastroenteritis
Latest Information Update: 20 Jan 2020
At a glance
- Drugs ORV 116E (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Adverse reactions
- Sponsors Bharat Biotech
Most Recent Events
- 05 Nov 2019 Status changed from recruiting to completed.
- 26 Sep 2019 New trial record